{"id":"W2155477677","doi":"10.1016/j.breast.2015.04.006","title":"One step forward, two steps back: The story of everolimus in advanced breast cancer","year":2015,"lang":"en","type":"article","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; University of Toronto; CancerCare Manitoba","funders":"","keywords":"Medicine; Everolimus; Bevacizumab; Breast cancer; Drug; Anticancer drug; Cancer; Cancer drugs; Clinical trial; Intensive care medicine; Oncology; Internal medicine; Pharmacology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007758602,0.0002743866,0.0005394118,0.00009897187,0.00009396816,0.00001058525,0.0004367566,0.00006899049,0.0002657269],"category_scores_gemma":[0.00003568633,0.0001686015,0.0001212351,0.0004621828,0.0004356564,0.0002014666,0.0001323105,0.0005643997,0.00007990828],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004387056,"about_ca_system_score_gemma":0.0004272956,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001073172,"about_ca_topic_score_gemma":0.0008870731,"domain_scores_codex":[0.9979305,0.0002484674,0.0003859808,0.0003265532,0.0006106314,0.0004978706],"domain_scores_gemma":[0.9981452,0.0001755707,0.0002482899,0.0009188291,0.0003206211,0.0001914729],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01369895,0.0007467201,0.03621593,0.0002169946,0.0005869627,0.00002368104,0.00654081,0.003712504,0.008076578,0.0009417019,0.001362151,0.927877],"study_design_scores_gemma":[0.02697689,0.0004445265,0.9292787,0.001498562,0.0004431091,0.002456787,0.01004499,0.0007310857,0.001595813,0.001726453,0.02404522,0.0007579004],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9511024,0.008741053,0.0007727633,0.03120629,0.0007513167,0.002069738,0.0005211357,0.000133519,0.004701822],"genre_scores_gemma":[0.9965506,0.00008942587,0.00048921,0.000991199,0.000436177,0.0001239351,0.000009436557,0.000067436,0.001242571],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9271191,"threshold_uncertainty_score":0.6875371,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02577296856479245,"score_gpt":0.2992484553007128,"score_spread":0.2734754867359204,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}